Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
es7M0XZQPECuvybX
